BREAKING NEWS: FDA Approves Sandoz’s Erelzi, biosimilar to Enbrel (etanercept)

Goodwin
Contact

The FDA today approved Sandoz’s application for a biosimilar version of Amgen’s Enbrel product (etanercept).   Sandoz’s biosimilar is called Erelzi.  It is the first biosimilar etanercept approved by FDA, and the third product to be approved under the BPCIA’s abbreviated approval pathway for biosimilars (first was Sandoz’s Zarxio (filgrastim) biosimilar to Amgen’s Neupogen, second was Celltrion’s Inflectra, a biosimilar to Janssen’s Remicade (infliximab)).

Sandoz’s etanercept product is currently the subject of litigation in Immunex v. Sandoz, in which a stipulated preliminary injunction has been entered by agreement of the parties.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide